Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy

PURPOSE: Gonadotropin-releasing hormone agonist (GnRHa) is a safe and effective therapy used to treat central precocious puberty (CPP). Although most studies have reported no significant difference in body mass index (BMI) in girls during and after GnRHa therapy, few studies have investigated change...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Kyung In, Lee, Hae Sang, Hwang, Jin Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Pediatric Endocrinology 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538302/
https://www.ncbi.nlm.nih.gov/pubmed/33017886
http://dx.doi.org/10.6065/apem.1938176.088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538302/
https://www.ncbi.nlm.nih.gov/pubmed/33017886
http://dx.doi.org/10.6065/apem.1938176.088

Ejemplares similares